ProCE Banner Activity

Gilteritinib With Induction and Consolidation Chemotherapy for Newly Diagnosed AML: Preliminary Phase I Results

Slideset Download
Conference Coverage
Preliminary data suggest novel combination of gilteritinib and chemotherapy has antileukemic effect in FLT3-mutated AML with acceptable safety.

Released: December 13, 2017

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

AstraZeneca

Celgene

Genentech TEXT Only

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Pharmacyclics Inc

Seagen

Takeda Oncology